Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Vyndaqel | tafamidis | Transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Minjuvi | tafasitamab | Diffuse large B-cell lymphoma (DLBCL) | Do not reimburse | Complete | ||
| Talzenna | talazoparib | Breast cancer | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | |||
| Elelyso | Taliglucerase alfa | Gaucher disease | Do not list | Complete | ||
| TBC | talquetamab | Relapsed or refractory multiple myeloma | Pending | |||
| Nucynta CR | Tapentadol | Pain, moderate to moderately severe | Do not list | Complete | ||
| Nucynta | tapentadol hydrochloride | pain, severe | Do not reimburse | Complete | ||
| Kimmtrak | tebentafusp | unresectable or metastatic uveal melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Active |
Last Updated : May 4, 2024